A role for hypocretin/orexin receptor-1 in cue-induced reinstatement of nicotine-seeking behavior

Neuropsychopharmacology. 2013 Aug;38(9):1724-36. doi: 10.1038/npp.2013.72. Epub 2013 Mar 21.

Abstract

Hypocretin/orexin signaling is critically involved in relapse to drug-seeking behaviors. In this study, we investigated the involvement of the hypocretin system in the reinstatement of nicotine-seeking behavior induced by nicotine-associated cues. Pretreatment with the hypocretin receptor-1 antagonist SB334867, but not with the hypocretin receptor-2 antagonist TCSOX229, attenuated cue-induced reinstatement of nicotine-seeking, which was associated with an activation of hypocretin neurons of the lateral and perifornical hypothalamic areas. In addition, relapse to nicotine-seeking increased the phosphorylation levels of GluR2-Ser880, NR1-Ser890, and p38 MAPK in the nucleus accumbens (NAc), but not in the prefrontal cortex. Notably, phosphorylation levels of NR1-Ser890 and p38 MAPK, but not GluR2-Ser880, were dependent on hypocretin receptor-1 activation. The intra-accumbens infusion of the protein kinase C (PKC) inhibitor NPC-15437 reduced nicotine-seeking behavior elicited by drug-paired cues consistent with the PKC-dependent phosphorylations of GluR2-Ser880 and NR1-Ser890. SB334867 failed to modify cue-induced reinstatement of food-seeking, which did not produce any biochemical changes in the NAc. These data identify hypocretin receptor-1 and PKC signaling as potential targets for the treatment of relapse to nicotine-seeking induced by nicotine-associated cues.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Benzoxazoles / pharmacology
  • Conditioning, Operant / drug effects
  • Conditioning, Operant / physiology*
  • Cues
  • Drug-Seeking Behavior / drug effects
  • Drug-Seeking Behavior / physiology*
  • Extinction, Psychological / drug effects
  • Extinction, Psychological / physiology
  • Hypothalamus / drug effects
  • Hypothalamus / physiology
  • Isoquinolines / pharmacology
  • Male
  • Mice
  • Microinjections
  • Naphthyridines
  • Nerve Tissue Proteins / metabolism
  • Neurons / drug effects
  • Neurons / physiology
  • Nicotine / administration & dosage
  • Nicotine / pharmacology*
  • Nicotinic Agonists / administration & dosage
  • Nicotinic Agonists / pharmacology*
  • Nucleus Accumbens / metabolism
  • Orexin Receptor Antagonists
  • Orexin Receptors / physiology*
  • Phosphorylation
  • Piperidines / administration & dosage
  • Piperidines / pharmacology
  • Prefrontal Cortex / metabolism
  • Protein Kinase Inhibitors / pharmacology
  • Pyridines / pharmacology
  • Receptors, AMPA / metabolism
  • Receptors, N-Methyl-D-Aspartate / metabolism
  • Self Administration
  • Signal Transduction / drug effects
  • Signal Transduction / physiology
  • Urea / analogs & derivatives
  • Urea / pharmacology
  • p38 Mitogen-Activated Protein Kinases / metabolism

Substances

  • 1-(2-methylbenzoxazol-6-yl)-3-(1,5)naphthyridin-4-yl urea
  • 1-(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)-3,3-dimethyl-2-((4-pyridinylmethyl)amino)-1-butanone
  • Benzoxazoles
  • Gprin1 protein, mouse
  • Hcrtr1 protein, mouse
  • Hcrtr2 protein, mouse
  • Isoquinolines
  • Naphthyridines
  • Nerve Tissue Proteins
  • Nicotinic Agonists
  • Orexin Receptor Antagonists
  • Orexin Receptors
  • Piperidines
  • Protein Kinase Inhibitors
  • Pyridines
  • Receptors, AMPA
  • Receptors, N-Methyl-D-Aspartate
  • NPC 15437
  • Nicotine
  • Urea
  • p38 Mitogen-Activated Protein Kinases
  • glutamate receptor ionotropic, AMPA 2